Retail
218 Articles
Layoffs were part of the business news yesterday. Enough people lost jobs in a series of three “downsizings” to reminds…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1…
Equities started the day with a solid move up, but lost momentum after about half an hour. The downward move…
These are some of Tuesday’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls. Aixtron SE (NASDAQ:…
Sales for the big pharmaceutical companies are expected to be hit by pricing pressure in Europe, a lack of urgent…
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability.…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Friday…
We may have just witnessed an oversold bounce in the stock market, or we may be in for more days…
The drug sector has become rather boring and investors already know all about the ongoing patent expiration threats that loom…
American Depository Receipts, or ADRs, are generally called American Depository Shares, or ADSs, now. We found after some routine screens…
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning.…
The method of using capital from the corporate treasury to return capital to shareholders via share repurchase programs has long…
These are some of this Tuesday’s key analyst upgrades, downgrades, and initiations seen in Wall Street research calls. Amgen Inc.…
These are some of this Wednesday’s top analyst upgrades, downgrades, and initiations seen in Wall Street research notes: Applied Materials…
There are many research calls this Thursday morning and these are just some of the top analyst upgrades, downgrades, and…
Our top personal finance-related articles today. Your wallet will thank you later.